New Pharm

Newron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company's lead marketed product, Xadago (safinamide), is approved globally as an add-on therapy for the treatment of Parkinson's disease. Newron's clinical pipeline is headlined by evenamide, a first-in-class voltage-gated sodium channel blocker currently in Phase 3 development for the treatment of schizophrenia, including treatment-resistant cases. Additionally, the company is exploring ralfinamide for various pain indications and has historically conducted research into rare neurological disorders like Rett syndrome. Headquartered in Italy with operations in Switzerland and the US, Newron leverages its expertise in ion channel modulation and neurotransmitter regulation to address significant unmet needs in neuropsychiatry.